Vaxart (NASDAQ:VXRT) Upgraded to "Buy" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Vaxart (NASDAQ:VXRT) to a Buy rating in a report issued on Friday.
• Shares opened at $0.67 (up about 1.5%), with a market capitalization near $161.1 million, a 12‑month range of $0.26–$0.84, and 50-/200‑day moving averages of $0.43/$0.39.
• Vaxart is a clinical‑stage biotech developing oral recombinant tablet vaccines built on a room‑temperature‑stable adenovirus vector platform designed to elicit systemic and mucosal immune responses.

Vaxart (NASDAQ:VXRT - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a "buy" rating in a report issued on Friday.

Vaxart Trading Up 1.5%

Shares of VXRT stock opened at $0.67 on Friday. The stock has a market capitalization of $161.08 million, a price-to-earnings ratio of -2.48 and a beta of 0.95. Vaxart has a 12-month low of $0.26 and a 12-month high of $0.84. The stock's 50-day moving average price is $0.43 and its 200-day moving average price is $0.39.

Institutional Investors Weigh In On Vaxart

Large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. purchased a new position in Vaxart during the 1st quarter worth approximately $31,000. Creative Planning purchased a new stake in Vaxart in the second quarter valued at $33,000. Invesco Ltd. grew its position in Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 70,568 shares during the period. Raymond James Financial Inc. grew its position in Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company's stock worth $107,000 after purchasing an additional 34,075 shares during the period. Finally, Jones Financial Companies Lllp raised its stake in shares of Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock valued at $196,000 after buying an additional 478,111 shares during the last quarter. Hedge funds and other institutional investors own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company's pipeline includes multiple vaccine candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.